Author
By Kate Greenwood Cross-Posted at Health Reform Watch In a recent, very moving, post about her son’s diagnosis with autism at age eight, blogger Amy Storch writes: “I guess I should mention the obvious —…
By Kate Greenwood Cross-Posted at Health Reform Watch Nearly three years ago, in July of 2011, Tara Adams Ragone wrote a blog post for Seton Hall Law’s Health Reform Watch blog entitled “Community Based Medicaid…
By Kate Greenwood Cross-Posted at Health Reform Watch As Kurt Karst reported at FDA Law Blog, here, drug maker Zogenix has filed a Motion for Temporary Restraining Order and Preliminary Injunction challenging Massachusetts’ decision to “prohibit…
By Kate Greenwood Cross-Posted at Health Reform Watch On April 21st, the Supreme Court will hear oral argument in Pom Wonderful v. The Coca-Cola Company, a case in which Pom sued Coke under Section 43(a) of…
By Kate Greenwood Cross-Posted at Heath Reform Watch Lately it seems that each passing day brings another article about the cost of orphan drugs. Earlier this week at FiercePharma, Tracy Staton reported that the United…
[Blogger’s Note: I am very pleased to share this post by my colleague at Seton Hall Law, Tara Adams Ragone, in which she discusses North Carolina Board of Dental Examiners v. FTC, drawing on both her…
By Kate Greenwood Cross-Posted at Health Reform Watch On Wednesday night, I went to a panel presentation sponsored by the group NYC Health Business Leaders on the roll out of New York State’s health insurance…
By Kate Greenwood Cross-Posted at Health Reform Watch Last week, vtdigger.org ran an interesting article by Laura Krantz on the difficulties pregnant women and new mothers who are addicted to drugs have accessing not just drug…
By Kate Greenwood Cross-Posted at Health Reform Watch For most women who work outside the home—Gisele Bundchen excepted—breastfeeding on the job is not an option. Pumping breast milk during the work day is more likely to be…
By Kate Greenwood Cross-Posted at Health Reform Watch At Regulatory Focus earlier this week, Alexander Gaffney wrote about what he characterized as “a torrent of studies” that FDA is conducting or has proposed conducting on prescription…
